News

Survival data from the first prospective, randomized biomarker validation trial in muscle-invasive bladder cancer presented at GU ASCO

Higher toxicity risk for women was known for chemotherapy, now also identified for immunotherapy and targeted therapy

Major financial hardship common after cancer diagnosis, despite insurance

Combo with immunotherapy drug can be effective in patients who are not good candidates for chemo

Analyses presented at ASH 2021 find statistical models can predict risk of early death with non-intensive AML therapy

Results at SABCS show assay has prognostic value that complements value of recurrence score in postmenopausal patients

RxPONDER finds postmenopausal women with HR+, HER2- breast cancer with 1-3 involved nodes and an RS of 25 or less can safely skip chemo

Forty years of publicly funded trials added 14 million years of life for cancer patients and profoundly affected cancer care guidelines

A blood serum test can identify which patients have slow-growing disease that might be controlled with an aromatase inhibitor alone.